SLE Preview: abolishing refractory with CAR-T and better B-cell therapies Despite advancements, some SLE patients rema
Tweet Content
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
Links
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies | Rhe…
https://buff.ly/3KPchE9
Show on Archive Page
On
Display in Search Results
On
PDQ
Off